DRL unveils anti-psychotic drug in U.S.

Dr. Reddy’s Laboratories (DRL) has introduced Fluphenazine Hydrochloride Tablets, USP, a drug indicated in the management of manifestations of psychotic disorders, in the U.S. market.

Launched following USFDA approval, the product is a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg. The Prolixin brand and generic had U.S. sales of about $134 million MAT for the most recent 12 months ending December, according to a DRL statement on Thursday that quoted IQVIA Health. DRL shares closed at ₹4,617.85, or up 0.35% apiece on the BSE.

You have reached your limit for free articles this month.

Subscription Benefits Include

Today’s Paper

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.

Unlimited Access

Enjoy reading as many articles as you wish without any limitations.

Personalised recommendations

A select list of articles that match your interests and tastes.

Faster pages

Move smoothly between articles as our pages load instantly.


A one-stop-shop for seeing the latest updates, and managing your preferences.


We brief you on the latest and most important developments, three times a day.

Support Quality Journalism.

*Our Digital Subscription plans do not currently include the e-paper, crossword and print.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.